This study found no increased rate of thyroid cancer in T2DM patients taking GLP‐1‐RAs versus SGLT2‐Is, but an imprecise increased rate in CWM patients taking GLP‐1‐RAs versus two different comparator weight management drugs (Figure 3). The gene discussed is SLC5A2; the disease is thyroid gland carcinoma.